AVR RD 05
Alternative Names: AVR-RD-05Latest Information Update: 25 Jun 2024
At a glance
- Originator University of Manchester
- Developer Tectonic Therapeutic
- Class Gene therapies; Haematopoietic stem cells therapies
- Mechanism of Action Gene transference; Iduronate sulfatase replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Mucopolysaccharidosis II
Most Recent Events
- 20 Jun 2024 AVROBIO has been merged with Tectonic Therapeutic to form Tectonic Therapeutic
- 30 Sep 2023 AVROBIO terminates licensing agreement with University of Manchester for AVR RD 05 in Mucopolysaccharidosis II, before September 2024
- 30 Sep 2023 Discontinued - Phase-I/II for Mucopolysaccharidosis II in United Kingdom (Parenteral), before September 2023